KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gilead Sciences (GILD) Cash from Financing Activities (2016 - 2026)

Gilead Sciences filings provide 17 years of Cash from Financing Activities readings, the most recent being -$1.3 billion for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 155.88% to -$1.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.7 billion, a 125.6% decrease, with the full-year FY2025 number at -$7.7 billion, down 125.6% from a year prior.
  • Cash from Financing Activities hit -$1.3 billion in Q4 2025 for Gilead Sciences, up from -$1.5 billion in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $2.3 billion in Q4 2024 to a low of -$3.5 billion in Q3 2021.
  • Median Cash from Financing Activities over the past 5 years was -$1.5 billion (2023), compared with a mean of -$1.6 billion.
  • Biggest five-year swings in Cash from Financing Activities: plummeted 1582.44% in 2021 and later surged 305.64% in 2024.
  • Gilead Sciences' Cash from Financing Activities stood at -$1.9 billion in 2021, then grew by 19.98% to -$1.6 billion in 2022, then rose by 29.28% to -$1.1 billion in 2023, then surged by 305.64% to $2.3 billion in 2024, then crashed by 155.88% to -$1.3 billion in 2025.
  • The last three reported values for Cash from Financing Activities were -$1.3 billion (Q4 2025), -$1.5 billion (Q3 2025), and -$1.6 billion (Q2 2025) per Business Quant data.